文献速递眼底病与葡萄膜炎

采用治疗-延长-停止方案管理且接受50次以上抗VEGF注射的新生血管性年龄相关性黄斑变性患者的长期一致治疗

Consistent Long-Term Therapy of Neovascular Age-Related Macular Degeneration Managed by 50 or More Anti-VEGF Injections Using a Treat-Extend-Stop Protocol.
PubMed 文献 · Ophthalmology · 2018-02-10

该回顾性病例研究分析了67例新生血管性年龄相关性黄斑变性(nAMD)患者(71眼)接受50次以上玻璃体腔内抗VEGF注射、按治疗-延长-停止(TES)方案管理的临床结果。第51次注射时平均视力较基线提高9.7个ETDRS字母(P < 0.001),末次随访时平均提高8.7个字母(P < 0.001),末次随访时35.2%的眼视力提高3行或以上。作者认为需要长期一致抗VEGF治疗的患者经TES方案管理可能维持或改善视力。

要点

  • 71眼(67例)接受≥50次抗VEGF注射并按TES方案管理,末次随访平均注射63.7次。
  • 第51次注射时平均视力65.3字母,较基线55.6字母提高9.7字母(P < 0.001)。
  • 末次随访平均视力64.3字母,较基线提高8.7字母(P < 0.001),35.2%眼提高≥3行。

核心结论

  • 在本研究中,患者在接受50次注射后平均获得2行ETDRS视力。
  • 本研究平均随访8年,末次随访时35.2%的眼视力提高3行或以上。
  • 需要长期一致抗VEGF治疗的患者经TES方案管理,可能能够维持或改善视力。

研究设计与样本

  • 回顾性病例研究,纳入私人视网膜诊所中诊断为nAMD且接受50次或以上玻璃体腔内抗VEGF注射的患者数据。
  • 共识别71眼(67例患者),排除因与AMD无关的诊断导致显著视力丧失的患者。
  • 收集基线视力(Snellen视力表转换为ETDRS字母)、年龄、随访时长、使用的抗VEGF药物及治疗间隔,检查至第51次注射及末次随访。

主要发现

  • 患者平均年龄83.0岁,女性占58.2%,男性占41.8%。
  • 平均初始视力55.6个ETDRS字母;第51次注射时平均视力65.3字母,较基线平均提高9.7字母(P < 0.001,Student配对t检验)。
  • 至第51次注射的平均随访时长6.5年,末次随访平均随访时长8年;末次随访平均注射次数63.7次。
  • 第51次随访时平均治疗间隔5.4周,末次检查平均随访间隔6.4周。
  • 末次随访时平均视力64.3字母,较基线平均提高8.7字母(P < 0.001);35.2%的眼视力提高3行或以上。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To examine the clinical results for patients with neovascular age-related macular degeneration (nAMD) who were managed with a treat-extend-stop (TES) protocol and received 50 or more injections of anti-vascular endothelial growth factor (VEGF) agents. DESIGN: Retrospective case study. PARTICIPANTS: Data for patients from a private retina practice meeting the following criteria were included: diagnosis of nAMD and having received 50 or more intravitreal injections of anti-VEGF agents. METHODS: The patients' baseline visual acuity (VA; obtained using Snellen charts and converted to Early Treatment Diabetic Retinopathy Study [ETDRS] letters), age, length of follow-up, anti-VEGF agents used, and interval between treatments were obtained. These data were examined through the 51st injection and at the last follow-up examination. Patients were excluded if they lost significant vision because of a diagnosis unrelated to AMD during therapy. MAIN OUTCOME MEASURES: Visual acuity and complications. RESULTS: Seventy-one eyes of 67 patients were identified who met inclusion criteria. The mean age of patients was 83.0 years. Women made up 58.2% of the study population, whereas men constituted 41.8%. The mean initial VA was 55.6 ETDRS letters. The mean duration of follow-up at the 51st visit for an injection was 6.5 years, and the mean duration of follow-up at the last visit was 8 years. The mean number of injections at final follow-up was 63.7. The mean interval between treatments at the 51st follow-up was 5.4 weeks, and the mean follow-up at the last examination was 6.4 weeks. Mean VA at the 51st injection was 65.3 letters, and the mean change from baseline was 9.7 letters (P < 0.001, Student paired t test). The mean vision gained at last follow-up was 8.7 letters from baseline (P < 0.001), or 64.3 letters. CONCLUSIONS: In this study, patients gained a mean of 2 ETDRS lines after 50 injections. This study had a mean follow-up of 8 years, and 35.2% of eyes had a 3-line or more gain in VA at the last follow-up examination. Patients who require consistent long-term anti-VEGF therapy, managed with a TES protocol, are likely able to maintain or improve their vision.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Adrean SD, Chaili S, Ramkumar H, et al. Consistent Long-Term Therapy of Neovascular Age-Related Macular Degeneration Managed by 50 or More Anti-VEGF Injections Using a Treat-Extend-Stop Protocol. Ophthalmology. 2018. PMID: 29439828. doi:10.1016/j.ophtha.2018.01.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。